OncoMatch/Clinical Trials/NCT03435796
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Is NCT03435796 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies non-drug interventions for neoplasms.
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: gene-modified T-cell therapy — previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial
Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama Birmingham · Birmingham, Alabama
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- Mayo Clinic Phoenix · Phoenix, Arizona
- Arizona Cancer Center · Scottsdale, Arizona
- Local Institution - 01021 · Tucson, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify